Finox Biotech hires three former Merck Serono managers

Finox Biotech is a biopharmaceutical company with its corporate headquarters in Burgdorf, Switzerland. Finox’ first product is bemfola, a biosimilar of GONAL-f. Finox Biotech was founded in 2007 by serial entrepreneur Willy Michel with a vision to become a leading company in the field of fertility therapies, by combining high quality Swiss medicines with innovative, award-winning delivery devices.

The company announced today three senior appointments:

Luigi Marro has been appointed to the position of Chief Financial Officer (CFO) of Finox Biotech. Luigi is a seasoned financial professional who has worked in the pharmaceutical industry for more than 20 years. Luigi joined Serono (latterly Merck Serono) in Italy following graduation in 1991 and worked within financial and managerial roles at Serono and Merck Serono for almost 20 years.

Ken Shields joins Finox Biotech as Executive Vice-President, Head of European Commercial Operations. Ken has a wealth of experience in sales and marketing roles in the area of women’s health and devices. He worked as UK Business Unit Head of Fertility and Endocrinology at Merck Serono between 2003 and 2011.

Nicole Stigemar has been appointed Executive Vice-President, Head of Marketing & Business Development. Nicole brings a deep knowledge of the fertility market and customers as well as an unrivalled understanding of the emerging markets to the company. Nicole’s experience includes 7 years at Merck Serono in marketing & sales roles in Europe and Emerging markets before spending 2 years leading marketing for a group of IVF clinics. Latterly Nicole spent 5 years in senior marketing & commercial development roles at Amgen.

Gavin Jelic-Masterton, Chief Executive of FINOX Biotech commented, “the appointment to our Leadership team of these three senior professionals, with a combined experience of almost 40 years in the fertility market, underlines our commitment and belief to hiring the most experienced executives to ensure a rapid and high uptake of Bemfola across Europe and the world. We are very excited to have Luigi, Ken and Nicole join Finox Biotech and are now fully ready to move to the next stage of our commercialisation plans”.